



Fourth quarter

- Gross order intake amounted to SEK 5,379 M (5,032), corresponding to an 18 percent increase in constant currency
- Net sales were SEK 3,667 M (4,008), corresponding to a 1 percent growth in constant currency
- Gross margin amounted to 38.5 (42.6) percent
- EBITA amounted to SEK 743 M (886), corresponding to an EBITA margin of 20.3 (22.1) percent
- Earnings per share was SEK 0.89 (1.07) before/after dilution
- Cash flow after continuous investments decreased by SEK 208 M to SEK 818 M (1,026)

Full year

- Gross order intake amounted to SEK 17,411 M (17,735), corresponding to a 6 percent growth in constant currency
- Net sales were SEK 13,763 M (14,601), corresponding to a 1 percent increase in constant currency
- Gross margin amounted to 40.8 (42.0) percent
- EBITA amounted to SEK 2,709 M (2,521), corresponding to an EBITA margin of 19.7 (17.3) percent
- Earnings per share was SEK 3.28 (2.84) before/after dilution
- Cash flow after continuous investments improved by SEK 1,454 M to SEK 1,706 M (252)

Dividend for fiscal year 2020/21

- The Board of Directors proposes a dividend of SEK 2.20 (1.80) per share (in two instalments) for the fiscal year 2020/21

New mid-term outlook

- Net sales CAGR of above 7 percent until 2024/25
- EBIT margin percent expansion until 2024/25
- A new dividend policy of at least 50 percent of net profit for the year

No significant events after the quarter

Group summary

SEK M	Q4			Full-year		
	2020/21	2019/20	Δ	2020/21	2019/20	Δ
Gross order intake	5,379	5,032	18%	17,411	17,735	6%
Net sales	3,667	4,008	1%	13,763	14,601	1%
Gross margin	38.5%	42.6%	-4.1 ppts	40.8%	42.0%	-1.2 ppts
EBITA	743	886	-16%	2,709	2,521	7%
EBITA margin	20.3%	22.1%	-1.8 ppts	19.7%	17.3%	2.4 ppts
EBIT	545	658	-17%	1,906	1,657	15%
Cash flow ¹	818	1,026	-20%	1,706	252	576%
Earnings per share, SEK ²	0.89	1.07	-16%	3.28	2.84	16%

¹ After continuous investments. ² Before / after dilution. ³ Based on constant currency.

This information is such that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the below mentioned contact persons at 07:30 CET on May 28, 2021. (REGMAR)

Forward-looking information. This report included forward-looking statements including, but not limited to, statements relation to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Some of these risks and uncertainties are described further in the section "Risk and uncertainties". Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations.

Fourth quarter

Accelerated order growth

During Elekta's fourth quarter, we drove strong order growth in all regions – both from market growth and market share gain – and we received our 100th Unity order. Installation volumes were similar to levels in the fourth quarter last year, still impacted by reduced access to hospitals, especially in emerging markets due to Covid. When summarizing the full year, we showed good order growth in a pandemic affected market, improved our EBITA on stable volumes and delivered our best annual cash flow ever.

Improved market conditions and accelerated growth

The market situation continued to improve in the fourth quarter. Many healthcare systems are starting to recover from the pandemic and investing to manage the cancer care needs that have not been met due to Covid. For Elekta the shift resulted in strong demand and order intake for our solutions, and we gained market share across all regions.

We see a recovery of installations in mature markets, but emerging markets are still lagging and expected to gradually improve in coming quarters. Our revenue in the quarter is in line with last year's levels. Gross margin continued to be negatively impacted by currency effects, higher supply chain and service costs due to the pandemic. Due to the rise in market activity our sales and marketing expenses increased compared to the last quarters. However, going forward, we expect to continue at lower expense levels in areas such as travel and conferences due to further digitalization and new ways of working. During the past year we have focused on building stronger processes to improve our stability in revenue and cash flow, and it is encouraging to see a more stable cash conversion between quarters. This year's cash flow was the best ever and we had a cash conversion of 82 percent.

Strong portfolio with Unity reaching the 100th order milestone

We continue to successfully drive our strategic focus on Precision Radiation Medicine and simultaneously building strong partnerships across the cancer care continuum. I am very pleased to see the interest and demand for our recently launched solutions: Harmony, Elekta Studio, MOSAIQ 3 and Lightning software. During the last year, Elekta strengthened the product portfolio across all our business lines and we will continue to invest in our solutions including our software architecture to further strengthen long term growth. Service is a key part of our business, especially during Covid, and we have seen our customer satisfaction score increase significantly during the year.

The Unity progressed well during the quarter, and we have now reached the important milestone of more than 100 Unity orders. It is inspiring to see the volume of clinical evidence in the Momentum study grow as we continue to advance the knowledge and application of MR-guided radiation therapy globally.

Continued market improvement expected in next quarter

During the next quarter we anticipate the overall market situation to continue to recover and our ability to install systems at customer sites to improve. We are convinced that long-term trends will support growth and investment in high-end radiation therapy equipment. At our Capital Markets Day, we will present our strategic priorities and explain the drivers behind the mid-term outlook.

I would like to thank all our customers, partners, and employees who have done a tremendous job under very difficult circumstances to secure continued cancer treatments for patients globally during the last year.



Gustaf Salford
President and CEO



18%
order growth

100th
Unity

milestone
achieved
in Q4

Order intake and order backlog

The pandemic and the ensuing delays in orders for radiation therapy equipment has created a pent-up demand, which will be relieved once countries and regions return to more normal conditions. The improvements in customers willingness to discuss and close orders seen in the previous quarter carried through to and further improved in the fourth quarter. Order growth in the fourth quarter was broad based with almost all business lines and regions growing strongly and with emerging markets being particularly strong. As confirmation of Elekta Unity's attractiveness, we signed the 100th order in the quarter. In total, gross order intake grew by 18 percent compared to the fourth quarter last year based on constant currency. Order backlog increased in constant currency, but as converted to closing exchange rates the order backlog amounted to SEK 33,293 M, compared to SEK 34,689 M on April 30, 2020. The negative translation effect amounted to SEK 3,524 M.

Gross order intake

SEK M	Q4				Full-Year			
	2020/21	2019/20	Δ ¹	Δ	2020/21	2019/20	Δ ¹	Δ
North and South America	1,947	1,963	13%	-1%	5,579	5,024	23%	11%
Europe, Middle East and Africa	1,909	1,906	7%	0%	6,353	7,029	-4%	-10%
Asia Pacific	1,523	1,163	46%	31%	5,479	5,682	5%	-4%
Group	5,379	5,032	18%	7%	17,411	17,735	6%	-2%

¹ Based on constant currency.

North and South America

Orders grew strongly by 13 percent in the fourth quarter, based on constant currency, with both North and South America growing. In North America the market is returning to more normal conditions on the back of a successful vaccination campaign. Capital equipment spending is returning, and customer access is steadily improving. Growth in North American orders was evenly distributed across the product portfolio. In South America the order situation also improved with strong performance in Colombia and Chile and in the Linac and Neuro business lines.

Europe, Middle East and Africa (EMEA)

Orders grew 7 percent based on constant currency with very strong performance in Middle East and Africa and solid development in Europe, despite the market contracting overall. Some mature European countries are showing signs of recovery from the pandemic with the launch of public tenders. The European growth was mainly driven by Germany and Belgium as well as southern European markets and there was a strong demand for Harmony. The Middle East had good order intake with strong growth in the United Arab Emirates and Yemen. In Africa development was strong with business lines Linac and Brachy leading the way and with South Africa and West African countries performing strongly, including the first order to Burkina Faso.

Asia Pacific

Orders grew a very strong 46 percent in constant currency in Asia Pacific. The continuing recovery in orders was broad based with many markets contributing, but mainly driven by very strong performance in China and India. The Chinese public market continues to be the main growth driver in the region. China's strong growth was related to most business lines, but particularly Linac. It was also driven by large orders from the General Hospital of People's Liberation Army. A number of East Asian countries and New Zealand contributed to the increased order intake in the quarter.

Gross order intake Group




Gross order intake North and South America



Gross order intake Europe, Middle East and Africa



Gross order intake Asia Pacific



Net sales

In contrast to the clear improvement in orders, sales continued to be negatively affected by the pandemic. This was mainly seen in Solutions sales reflecting the time lag between countries opening up, and product shipments and installations returning to more normal levels. Based on constant currency net sales increased by 1 percent in the fourth quarter. In SEK net sales decreased by 9 percent to SEK 3,667 M (4,008).

Service grew 6 percent based on constant currency in the quarter returning to more normal growth levels after the negative impact of the pandemic in the third quarter. Solutions sales declined by 2 percent in constant currency, with positive development in the Linac and Neuro business lines. Geographically, sales in Europe, Middle East and Africa increased in the quarter.

Net sales per region

SEK M	Q4				Full-year			
	2020/21	2019/20	Δ ¹	Δ	2020/21	2019/20	Δ ¹	Δ
North and South America	1,079	1,255	-2%	-14%	3,888	4,482	-4%	-13%
Europe, Middle East and Africa	1,522	1,571	3%	-3%	5,140	5,547	-2%	-7%
Asia Pacific	1,066	1,182	0%	-10%	4,735	4,572	11%	4%
Group	3,667	4,008	1%	-9%	13,763	14,601	1%	-6%

¹ Based on constant currency.

North and South America

In North and South America net sales declined 2 percent based on constant currency. The U.S. came in at 0 percent. The sales recovery in North America was slower than for orders with longer time between recovery and product shipment and installation. In South America the situation was still challenging with a clear negative effect due to the pandemic. Sales declined based on negative development in several countries such as Argentina and Colombia.

Europe, Middle East and Africa (EMEA)

Net sales grew by 3 percent in constant currency in Europe, Middle East and Africa. Net sales in Europe were strong, with Italy, France and Germany showing good growth in installations. Emerging markets were more challenging with negative development due to the pandemic in Africa and the Middle East. The decline was most significant in the Middle East with fewer installations in some markets such as Turkey. Despite a challenging situation in Africa, Morocco showed good revenue growth.

Asia Pacific

Net sales in Asia Pacific were flat based on constant currency with sales growing in China, India and Japan. In Japan, sales were particularly strong in the quarter with double digit growth. Chinese installations continued to show good momentum. Outside these markets Covid continued to have a negative effect on sales.

6%
revenue growth
in service

Net sales by quarter



Net sales by RTM



Double-digit
growth rate in Japan

Full year

Net sales

Solutions and service sales

The pandemic has negatively impacted sales in the year. Solutions sales declined 1 percent and was also relatively volatile between quarters. Service sales was stable, although also negatively affected by Covid, and grew 5 percent. The MR-Linac and Neuro business lines showed growth in the year with the other business lines posting small declines. At the end of the period Elekta had an installed base of approximately 6,650 devices, of which approximately 4,750 units are Linacs, MR-Linacs or Leksell Gamma Knives.

Net sales per product

SEK M	Q4		Δ ¹		Full-year		Δ ¹	
	2020/21	2019/20			2020/21	2019/20		
Solutions	2,254	2,524	-2%	-11%	8,175	8,846	-1%	-8%
Service	1,413	1,485	6%	-5%	5,588	5,755	5%	-3%
Total	3,667	4,008	1%	-9%	13,763	14,601	1%	-6%

¹ Based on constant currency.

Earnings

Gross margin was 40.8 percent (42.0) for the full year. The decrease compared to last year was to a large part explained by negative impact from currency, but also higher supply-chain costs and higher cost to serve our installed base during the pandemic.

On an annual basis operating expenses decreased by 6 percent in constant currencies. The decrease was driven by lower selling expenses due to Covid-19 cost control measures. R&D expenditure decreased during the year, although adjusted for the net of capitalization and amortization, see investments and amortization/depreciation section below, R&D costs increased some and corresponded to 11 percent (10) of net sales. In the fourth quarter operating expense was impacted by higher personnel costs from incentives and unused vacations, as well as one-off legal fee for multi-year process of SEK 35 M from the successful conclusion of the humediQ litigation.

EBITA was SEK 2,709 M (2,521) representing a margin of 19.7 percent (17.3). The improvement in EBITA margin is explained by lower selling expenses and R&D costs. Operating result (EBIT) was SEK 1,906 M (1,657).

Net financial items amounted to SEK -277 M (-203). The key driver was lower interest income due to lower interest rates and increased interest expenses as a result of a higher level of gross debt. In addition, a USD 50 M loan was repaid in advance, which added an interest expense of about SEK 40 M. Profit before tax amounted to SEK 1,630 M (1,454) and tax amounted to SEK -377 M (-370), representing a tax rate of 23.1 percent (25.4).

Net income amounted to SEK 1,253 M (1,084) and earnings per share amounted to SEK 3.28 (2.84) before and after dilution. Return on shareholders' equity amounted to 16 percent (14) and return on capital employed was 12 percent (12).

19.7%
EBITA margin

EBITA



11%
R&D expenditure
of net sales

Full year

Investments and amortization/depreciation

The net of capitalized and amortized development costs in the R&D function decreased to SEK -2 M (-176). This was explained by higher capitalization levels for R&D as more projects reached this stage of the development compared to last year, but also lower amortizations.

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
R&D, net	51	-1	-2	-176
Capitalization	218	188	676	555
Amortization	-167	-188	-678	-731
Other, net	-2	-4	-6	-7
Total, net	49	-4	-9	-183

Investments in intangible assets amounted to SEK 678 M (566). The increase was mainly related to the acquisition of Kaiku Health. Investments in tangible assets were SEK 167 M (196). Amortization of intangible assets and depreciation of tangible fixed assets amounted to a total of SEK 1,204 M (1,275).

Improved cash flow

Cash flow

Cash flow from operating activities was SEK 2,551 M (1,014). Cash flow after continuous investments was SEK 1,706 M (252). The strong improvement in cash flow was mainly related to lower increase in working capital compared to last year, see working capital section below. In addition, earnings improved compared to last year.

82%
operational cash conversion

Cash flow (extract)

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
Operating cash flow	667	973	2,660	2,526
Change in working capital	447	272	-109	-1,512
Cash flow from operating activities	1,114	1,244	2,551	1,014
Continuous investments	-296	-218	-845	-761
Cash flow after continuous investments	818	1,026	1,706	252
Operational cash conversion	130%	123%	82%	35%

Full year

Working capital

Net working capital decreased by SEK 98 M to SEK -977 M (-879) corresponding to -7 percent (-6) of net sales for the year. Compared to last year most working capital items decreased, although accrued income increased, which was mainly related to MR-Linac and projects in China, Japan and Europe. The positive impacts from inventory were related to a normalization after previous build-up. All individual working capital items were impacted by currency movements while the net effect on working capital from currencies was limited. For more information, see page 26.

Financial position


Cash and cash equivalents and short-term investments amounted to SEK 4,411 M (6,470). Interest-bearing liabilities excluding lease liabilities amounted to SEK 5,184 M (8,102). Net debt amounted to SEK 774 M (1,632). Net debt in relation to EBITDA was 0.25 (0.56). The average maturity of interest-bearing liabilities was 2.9 years.

Net debt

SEK M	Apr 30 2021	Apr 30 2020	Jan 31 2021
Long-term interest-bearing liabilities	3,043	7,101	4,950
Short-term interest-bearing liabilities	2,141	1,001	831
Cash and cash equivalents and short-term investments	-4,411	-6,470	-4,640
Net debt	774	1,632	1,140
Long-term lease liabilities	854	1,043	849
Short-term lease liabilities	200	213	188
Net debt including lease liabilities	1,828	2,888	2,178

The exchange rate effect from the translation of cash and cash equivalents amounted to SEK -321 M (-5). The translation difference in interest-bearing liabilities amounted to SEK -216 M (25).

Working capital



0.25
Net debt/EBITDA

Full year

Risk and uncertainties

Elekta's presence in a large number of geographical markets exposes the Group to political and economic risks on a global scale and/or in individual countries. For more details, please see Annual Report 2019/20, page 30.

Impact from Covid-19

Due to ongoing uncertainties related to the development of the pandemic, Elekta has not published an outlook for the fiscal year 2020/21.

Covid-19 continued to have a negative impact on Elekta's business throughout the year. Overall, Elekta has managed well through the crisis, balancing the safety of employees with the commitments to customers and their patients. The treatment utilization rate in Elekta's installed base has been maintained at normal levels. The production sites of linacs in Crawley, UK and Beijing, China has been fully operational as has the production facilities of Brachy in the Netherlands and Neuro in Sweden. The continuity of Elekta's supply chain has benefitted from a dual source strategy and the fact that Elekta and its suppliers being labelled essential business by relevant government authorities. There are no major short-term supply issues.

Elekta has not received any government grants in Sweden. On a global basis Elekta has received government grants amounting to approximately SEK 60 M for the full year of 2020/21.

Find more detailed information about our policies in the Annual Report 2019/20

Significant events

Fourth quarter

Elekta wins lawsuit against humediQ GmbH

In March, Elekta announced that the London Court of International Arbitration (LCIA) has awarded in favor of Elekta in a dispute with Livian GmbH (formerly humediQ GmbH). The arbitration is now finally settled whereby all claims against Elekta group companies are rejected in full.


Elekta Monaco® receives clearance by FDA

In March, Elekta announced that its latest solution for proton therapy, Monaco® treatment planning for protons, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Monaco is a component of Elekta's Treatment Management Solution, which provides a full-featured environment for delivering proton therapy.

Changes in Executive Management

In February, Johan Adebäck was appointed as permanent Chief Financial Officer with immediate effect. He has held the position of Acting CFO since June 2, 2020. Prior to the Acting CFO position, Johan Adebäck had been Group Treasurer at Elekta since 2004, responsible for Treasury, Taxes, Customer Financing, Operational accounting and Customer Credit Risk.

During the fourth quarter Ioannis Panagiotelis, Chief Marketing and Sales Officer and EVP for APAC, Japan and South America, left Elekta and the Executive Management team.



Full year

Elekta named one of the world's most ethical companies

In February, Elekta announced that it has, for third year straight, been recognized as one of the World's Most Ethical Companies® by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices. The honor is bestowed upon companies that influence the business community and societies around the world in order to drive positive change.

Elekta acquires distributor and establishes an office in Egypt

In February, Elekta signed an agreement to acquire the oncology division of its previous distributor and announced that it will establish a permanent office in Cairo, Egypt, to address the shortage of radiotherapy delivery systems and software solutions that play an integral part in treating cancer and brain disorders. Closing of the acquisition is intended to take place in the first quarter of fiscal year 2021/22.

Third quarter¹

- Gustaf Salford appointed Elekta's President and CEO
- Elekta Studio – 3D image-guided brachytherapy was introduced
- Major milestones achieved in MR-guided radiotherapy
- Elekta divests its stake in ViewRay

Second quarter¹

- Fewer members in the Executive Management team
- Elekta Unity received clearance by China's NMPA
- MDR certificates for the linac portfolio
- Elekta introduces Harmony

First quarter¹

- Dr Richard Hausmann resigned as President and CEO
- Changes in Executive Management (Andrew Wilson and Larry Biscotti became permanent members, Oskar Bosson left Elekta)
- Acquisition of Kaiku Health
- GenesisCare made major investment in Elekta cancer treatment equipment
- Elekta launched Leksell Gamma Knife Lightning

Legal disputes²

humediQ

See significant events above.

ZAP Surgical Systems, Inc

In the ongoing patent infringement dispute in the US and Germany against ZAP Surgical Systems, Inc, the US patent was reverted back to the US Patent Office's Patent Trial and Appeal Board (PTAB), resulting in a finding of partial invalidity of the parts of the patent that were challenged. Elekta is currently reviewing whether to appeal the PTAB decision. The US decision should have no bearing on the parallel infringement suit in Germany.

¹ For more details about the previous significant events please see respective quarterly report.

² The material legal disputes reported here are either new cases or previous cases with changes in the interim period. For previous reported cases please see Elekta's Annual reports.



Full year

Employees

The average number of employees during the period was 4,194 (4,117).
The average number of employees in the Parent Company was 45 (41).

Shares

Total number of registered shares on April 30, 2021 was 383,568,409 of which 14,980,769 were A-shares and 368,587,640 B-shares. On April 30, 2021 1,485,289 shares were treasury shares held by Elekta.

Stockholm, May 28, 2021

Gustaf Salford
President and CEO

This report has not been reviewed by the Company's auditors.

Fourth quarter and full year

Consolidated income statement – condensed

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
Net sales	3,667	4,008	13,763	14,601
Cost of products sold	-2,256	-2,301	-8,153	-8,464
Gross income	1,411	1,708	5,610	6,138
Selling expenses	-314	-380	-1,143	-1,444
Administrative expenses	-292	-250	-1,086	-1,093
R&D expenses	-344	-395	-1,486	-1,657
Other operating income and expenses	-12	58	-85	11
Exchange rate differences	97	-82	97	-298
Operating result	545	658	1,906	1,657
Financial items, net	-108	-77	-277	-203
Profit before tax	437	581	1,630	1,454
Income taxes	-97	-173	-377	-370
Net income	341	407	1,253	1,084
<i>Net income attributable to</i>				
Parent Company shareholders	341	408	1,254	1,084
Non-controlling interests	0	0	-1	0
<i>Average number of shares</i>				
Before dilution, millions	382	382	382	382
After dilution, millions	382	382	382	382
<i>Earnings per share</i>				
Before dilution, SEK	0.89	1.07	3.28	2.84
After dilution, SEK	0.89	1.07	3.28	2.84

Fourth quarter and full year

Consolidated statement of comprehensive income

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
Net income	341	407	1,253	1,084
Other comprehensive income:				
<i>Items that will not be reclassified to the income statement:</i>				
Remeasurements of defined benefit pension plans	-3	-8	-3	-8
Change in fair value of equity instruments	-6	-107	206	-104
Tax	3	25	-43	24
Total items that will not be reclassified to the income statement	-6	-90	160	-88
<i>Items that subsequently may be reclassified to the income statement:</i>				
Revaluation of cash flow hedges	-52	-36	231	37
Translation differences from foreign operations	30	-1	-838	30
Tax relating to revaluation of cash flow hedges	12	8	-48	-7
Total items that subsequently may be reclassified to the income statement	-9	-30	-654	60
Other comprehensive income for the period	-15	-120	-494	-27
Total comprehensive income for the period	326	287	759	1,057
<i>Comprehensive income attributable to:</i>				
Parent Company shareholders	327	287	760	1,057
Non-controlling interests	-1	0	-1	0

Result overview

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
Operating result/EBIT	545	658	1,906	1,657
<i>Amortizations of intangible assets:</i>				
Capitalized development costs	169	199	685	746
Assets relating to business combinations	28	29	118	119
EBITA	743	886	2,709	2,521

Fourth quarter and full year

Consolidated balance sheet statement – condensed

SEK M	Apr 30 2021	Apr 30 2020
Non-current assets		
Intangible assets	8,779	9,469
Right-of-use assets	953	1,156
Other tangible fixed assets	897	968
Financial assets	533	748
Deferred tax assets	436	504
Total non-current assets	11,597	12,845
Current assets		
Inventories	2,283	2,748
Accounts receivable	3,281	3,379
Accrued income	1,772	1,526
Other current receivables	1,502	1,505
Cash and cash equivalents	4,411	6,407
Total current assets	13,247	15,566
Total assets	24,844	28,411
Equity attributable to Parent Company shareholders	8,197	8,113
Non-controlling interests	0	1
Total equity	8,197	8,113
Non-current liabilities		
Long-term interest-bearing liabilities	3,043	7,101
Long-term lease liabilities	854	1,043
Other long-term liabilities	810	853
Total non-current liabilities	4,707	8,997
Current liabilities		
Short-term interest-bearing liabilities	2,141	1,001
Short-term lease liabilities	200	213
Accounts payable	1,016	1,025
Advances from customers	3,759	4,103
Prepaid income	2,082	2,226
Accrued expenses	1,837	1,703
Other current liabilities	905	1,030
Total current liabilities	11,941	11,300
Total equity and liabilities	24,844	28,411

Fourth quarter and full year

Changes in consolidated equity – condensed

SEK M	Full-year	
	2020/21	2019/20
Attributable to Parent Company shareholders		
Opening balance	8,113	7,778
Opening balance adjustment due to IFRS 16	-	-31
Comprehensive income for the period	760	1,057
Incentive programs	12	-3
Dividend	-688	-688
Total	8,197	8,113
Attributable to non-controlling interests		
Opening balance	1	1
Comprehensive income for the period	-1	0
Total	0	1
Closing balance	8,197	8,113

Consolidated cash flow statement – condensed

SEK M	Q4		Full-year	
	2020/21	2019/20	2020/21	2019/20
Profit before tax	437	581	1,630	1,454
Amortization and depreciation	308	350	1,204	1,275
Interest net	81	62	204	150
Other non-cash items	44	67	307	54
Interest received and paid	-90	-54	-220	-145
Income taxes paid	-114	-33	-465	-261
Operating cash flow	667	973	2,660	2,526
Changes in inventories	158	163	270	-116
Changes in operating receivables	182	413	-772	-434
Changes in operating liabilities	107	-305	393	-962
Change in working capital	447	272	-109	-1,512
Cash flow from operating activities	1,114	1,244	2,551	1,014
Investments intangible assets	-218	-195	-678	-566
Investments other assets	-77	-23	-167	-196
Continuous investments	-296	-218	-845	-761
Cash flow after continuous investments	818	1,026	1,706	252
Short-term investments	4	46	60	-26
Business combinations, divestments and investments in other shares	-42	-91	172	-511
Cash flow after investments	781	981	1,938	-284
Dividends	-344	-344	-688	-688
Cash flow from other financing activities	-704	3,447	-2,917	3,311
Cash flow for the period	-267	4,084	-1,667	2,339
Change in cash and cash equivalents during the period				
Cash and cash equivalents at the beginning of the period	4,640	2,392	6,407	4,073
Cash flow for the period	-267	4,084	-1,667	2,339
Exchange rate differences	37	-69	-329	-5
Cash and cash equivalents at the end of the period	4,411	6,407	4,411	6,407

Parent company

Income statement and statement of comprehensive income - condensed

SEK M	Full-year	
	2020/21	2019/20
Operating expenses	-27	-131
Financial net	468	218
Income after financial items	441	87
Appropriations	-	14
Tax	-14	36
Net income	427	137
Statement of comprehensive income		
Net income	427	137
Other comprehensive income	-	-
Total comprehensive income	427	137

Balansräkning i sammandrag

Mkr	30 apr	30 apr
	2021	2020
Anläggningstillgångar		
Immateriella tillgångar	46	53
Andelar i koncernföretag	2,590	2,251
Fordringar hos koncernföretag	2,194	2,391
Övriga finansiella tillgångar	94	326
Uppskjutna skattefordringar	27	41
Summa anläggningstillgångar	4,951	5,062
Omsättningstillgångar		
Fordringar hos koncernföretag	2,895	4,248
Övriga kortfristiga fordringar	39	81
Likvida medel	3,421	5,387
Summa omsättningstillgångar	6,355	9,716
Summa tillgångar	11,306	14,778
Eget kapital	2,087	2,346
Obeskattade reserver	-	-
Långfristiga skulder		
Långfristiga räntebärande skulder	3,043	7,101
Långfristiga avsättningar	40	10
Summa långfristiga skulder	3,083	7,111
Kortfristiga skulder		
Kortfristiga räntebärande skulder	2,141	942
Skulder till koncernföretag	3,858	4,283
Kortfristiga avsättningar	-	1
Övriga kortfristiga skulder	137	95
Summa kortfristiga skulder	6,136	5,321
Summa eget kapital och skulder	11,306	14,778

Accounting principles

This interim report is prepared, with regards to the Group, according to IAS 34 and the Swedish Annual Accounts Act and, with regards to the Parent Company, according to the Swedish Annual Accounts Act and RFR 2. The accounting principles applied are consistent with those presented in Note 1 of the Annual Report 2019/20.

New or revised standards and interpretations, not yet applied, are not considered to have a material impact on the Elekta Group's financial statements.

All figures are stated in SEK M and, accordingly, rounding differences can occur.

Accounting principle government grants

Government grants relate to financial grants from governments, public authorities and similar local, national, or international bodies. These are recognized when there is a reasonable assurance that the grants will be received and that Elekta will comply with the conditions attached to them. Government grants relating to expenses are recognized in the income statement as a deduction of such related expenses. Government grants relating to assets are included in the balance sheet as prepaid income and recognized as income over the useful life of the assets.

Related party transactions

Related party transactions are described in note 35 in the Annual Report for 2019/20. No material changes have taken place in relations or transactions with related parties companies compared with the description in the Annual report 2019/20.

Divestment of other shares in ViewRay

In January, Elekta announced that it has sold its 7.3 percent of the out-standing common stock (11,501,597 shares) in ViewRay, Inc. Elekta has no remaining shares in ViewRay after the transaction.

Elekta has treated the acquisition of other shares in ViewRay as equity investment designated as measured at fair value through other comprehensive income with gains and losses remaining in other comprehensive income, without recycling to profit or loss upon derecognition. Therefore, the effect of the divestment remains in other comprehensive income and the result of the divestment is a gain of SEK 208 M before tax for the first nine months 2020/21. The result effect in other comprehensive income during the time of the ownership of the shares in ViewRay, since inception of the investment in Q3 2019/20, is amounting to SEK 101 M before tax.

Exchange rates

Country	Currency	Average rate			Closing rate		
		May - Apr			Apr 30		
		2020/21	2019/20	Δ ¹	2021	2020	Δ ¹
Euroland	1 EUR	10.293	10.681	-4%	10.151	10.694	-5%
Great Britain	1 GBP	11.549	12.200	-5%	11.682	12.278	-5%
Japan	1 JPY	0.083	0.089	-7%	0.077	0.092	-17%
United States	1 USD	8.764	9.637	-9%	8.377	9.847	-15%

¹ April 30, 2021 vs April 30, 2020.

For Group companies with a functional currency other than Swedish kronor, order intake and income statements are translated at average exchange rates for the reporting period, while order book and balance sheets are translated at closing exchange rates.

Fourth quarter and full year

Segment reporting

Elekta applies geographical segmentation. Order intake, net sales and contribution margin for the respective regions are reported to Elekta's CFO and CEO (chief operating decision makers). The regions' expenses are directly attributable to the respective regions' reported figures including cost of products sold. Global costs for R&D, marketing, management of product supply centres and Parent Company are not allocated per region. Currency exposure is concentrated to product supply centres. The majority of exchange differences in operations are reported in global costs.

Elekta's operations are characterized by significant quarterly variations in volumes and product mix, which have a direct impact on net sales and profits. This is accentuated when the operation is split into segments, as is the impact of currency fluctuations between the years. Revenue from solutions are recognized at a point in time and revenue from services are recognized over time.

Q4 2020/21

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total	% of net sales
Net sales	1,079	1,522	1,066	-	3,667	
Regional expenses	-737	-950	-753	-	-2,440	67%
Contribution margin	341	573	312	-	1,226	33%
Contribution margin, %	32%	38%	29%			
Global costs	-	-	-	-681	-681	19%
Operating result	341	573	312	-681	545	15%
Net financial items	-	-	-	-108	-108	
Profit before tax	341	573	312	-789	437	

Q4 2019/20

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total	% of net sales
Net sales	1,255	1,571	1,182	-	4,008	
Regional expenses	-735	-1,089	-777	-	-2,601	65%
Contribution margin	520	482	405	-	1,407	35%
Contribution margin, %	41%	31%	34%			
Global costs	-	-	-	-750	-750	19%
Operating result	520	482	405	-750	658	16%
Net financial items	-	-	-	-77	-77	
Profit before tax	520	482	405	-827	581	

Full-year 2020/21

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total	% of net sales
Net sales	3,888	5,140	4,735	-	13,763	
Regional expenses	-2,386	-3,260	-3,227	-	-8,874	64%
Contribution margin	1,502	1,880	1,507	-	4,889	36%
Contribution margin, %	39%	37%	32%			
Global costs	-	-	-	-2,983	-2,983	22%
Operating result	1,502	1,880	1,507	-2,983	1,906	14%
Net financial items	-	-	-	-277	-277	
Profit before tax	1,502	1,880	1,507	-3,259	1,630	

Fourth quarter and full year

Full-year 2019/20

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total	% of net sales
Net sales	4,482	5,547	4,572	-	14,601	
Regional expenses	-2,704	-3,786	-3,142	-	-9,633	66%
Contribution margin	1,778	1,760	1,430	-	4,968	34%
Contribution margin, %	40%	32%	31%			
Global costs	-	-	-	-3,312	-3,312	23%
Operating result	1,778	1,760	1,430	-3,312	1,657	11%
Net financial items	-	-	-	-203	-203	
Profit before tax	1,778	1,760	1,430	-3,515	1,454	

Net sales by product type

Q4 2020/21

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total
Solutions	530	988	736	-	2,254
Service	549	534	330	-	1,413
Total	1,079	1,522	1,066	-	3,667

Q4 2019/20

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total
Solutions	639	1,044	841	-	2,524
Service	616	527	341	-	1,485
Total	1,255	1,571	1,182	-	4,008

Full-year 2020/21

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total
Solutions	1,563	3,126	3,485	-	8,175
Service	2,325	2,014	1,249	-	5,588
Total	3,888	5,140	4,735	-	13,763

Full-year 2019/20

SEK M	North and South America	Europe, Middle East and Africa	Asia Pacific	Other / Group-wide	Group total
Solutions	1,965	3,577	3,305	-	8,846
Service	2,518	1,970	1,268	-	5,755
Total	4,482	5,547	4,572	-	14,601

Financial instruments

The table below shows the fair value of the Group's financial instruments, for which fair value is different than carrying value. The fair value of all other financial instruments is assumed to correspond to the carrying value.

SEK M	Apr 30, 2021		Apr 30, 2020	
	Carrying amount	Fair value	Carrying amount	Fair value
Long-term interest-bearing liabilities	3,043	3,250	7,101	7,503
Long-term lease liabilities	854	854	1,043	1,043
Short-term interest-bearing liabilities	2,141	2,174	1,001	1,002
Short-term lease liabilities	200	200	213	213

The Group's financial assets and financial liabilities, which have been measured at fair value, have been categorized in the fair value hierarchy. The different levels are defined as follows:

Level 1: Quoted prices on an active market for identical assets or liabilities

Level 2: Other observable data than quoted prices included in Level 1, either directly (that is, price quotations) or indirectly (that is, obtained from price quotations)

Level 3: Data not based on observable market data

Financial instruments measured at fair value

SEK M	Level	Apr 30, 2021	Apr 30, 2020
FINANCIAL ASSETS			
Financial assets measured at fair value through profit or loss:			
Derivative financial instruments – non-hedge accounting	2	32	81
Short-term investments	1	-	62
Short-term investments classified as cash equivalents	1	792	1,241
Financial assets measured at fair value through other comprehensive income:			
Equity instruments	1	60	297
Derivatives used for hedging purposes:			
Derivative financial instruments – hedge accounting	2	212	25
Total financial assets		1,096	1,707
FINANCIAL LIABILITIES			
Financial liabilities at fair value through profit or loss:			
Derivative financial instruments – non-hedge accounting	2	29	55
Other liabilities (contingent considerations)	3	120	105
Derivatives used for hedging purposes:			
Derivative financial instruments – hedge accounting	2	13	58
Total financial liabilities		162	217

The fair value of accounts receivables, other current and non-current receivables, cash and cash equivalents, accounts payable and other current and non-current liabilities is estimated to be equal to their carrying amount.

Key figures and data

Key figures

	May - Apr ¹		May - Apr			May - Apr
	2015/16	2016/17	2017/18	2018/19	2019/20	2020/21
Gross order intake, SEK M	13,821	14,064	14,493	16,796	17,735	17,411
Net sales, SEK M	11,221	10,704	11,573	13,555	14,601	13,763
Order backlog, SEK M	18,239	22,459	27,974	32,003	34,689	33,293
Operating result, SEK M	423	598	1,845	1,696	1,657	1,906
Operating margin, %	3.8	5.6	15.9	12.5	11.3	13.9
Shareholders' equity, SEK M	6,412	6,774	6,987	7,779	8,113	8,197
Return on shareholders' equity, %	2	2	22	17	14	16
Net debt, SEK M	2,677	1,889	803	439	1,632	774
Operational cash conversion, %	111	145	95	61	35	82
Average number of employees	3,677	3,581	3,702	3,798	4,117	4,194

¹ Calculation based on IAS18.

Data per share

	May - Apr ¹		May - Apr			May - Apr
	2015/16	2016/17	2017/18	2018/19	2019/20	2020/21
Earnings per share						
before dilution, SEK	0.36	0.33	3.53	3.14	2.84	3.28
after dilution, SEK	0.36	0.33	3.53	3.14	2.84	3.28
Cash flow per share						
before dilution, SEK	1.00	2.69	3.79	2.48	-0.74	5.05
after dilution, SEK	1.00	2.69	3.79	2.48	-0.74	5.05
Shareholders' equity per share						
before dilution, SEK	16.79	17.73	18.29	20.36	21.23	21.45
after dilution, SEK	16.79	17.73	18.29	20.36	21.23	21.45
Average number of shares						
before dilution, 000s	381,288	381,306	382,027	382,027	382,062	382,083
after dilution, 000s	381,288	381,306	382,027	382,027	382,062	382,083
Number of shares at closing						
before dilution, 000s ²	381,288	382,027	382,027	382,027	382,083	382,083
after dilution, 000s	381,288	382,027	382,027	382,027	382,083	382,083

¹ Calculation based on IAS18.

² Number of registered shares at closing excluding treasury shares (1,485,289 per April 30, 2021).

Fourth quarter and full year

Data per quarter

	2018/19		2019/20			2020/21			
SEK M	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Gross order intake	5,401	4,390	4,036	4,276	5,032	4,451	3,627	3,954	5,379
Net sales	4,086	3,228	3,709	3,656	4,008	2,981	3,534	3,581	3,667
EBITA	985	448	539	648	886	551	752	664	743
Operating result	755	236	321	443	658	335	559	468	545
Cash flow from operating activities	1,547	-629	419	-21	1,244	211	535	690	1,114

Order intake growth based on constant currency

	2018/19		2019/20			2020/21			
	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
North and South America, %	9	0	29	-43	0	66	-12	41	13
Europe, Middle East and Africa, %	18	64	-21	9	-17	-20	20	-17	7
Asia Pacific, %	-8	31	23	-6	-13	-12	-12	8	46
Group, %	8	32	5	-11	-10	4	-2	2	18

No significant events after the quarter

Alternative performance measures

Alternative Performance Measures (APMs) are measures and key figures that Elekta's management and other stakeholders use when managing and analyzing Elekta's business performance. These measures are not substitutes, but rather supplements to financial reporting measures prepared in accordance with IFRS. Key figures and other APMs used by Elekta are defined on www.elekta.com/investors/financials/definitions. Definitions and additional information on APMs can also be found on pages 143-146 in the Annual Report 2019/20.

Order and sales growth based on constant currency

Elekta's order intake and sales are, to a large extent, reported in subsidiaries with other functional currencies than SEK, which is the group reporting currency. In order to present order and sales growth on a more comparable basis and to show the impact of currency fluctuations, order and sales growth based on constant currency are presented. The schedules below present growth based on constant currency reconciled to the total growth reported in accordance with IFRS.

Change gross order intake

	North and South America		Europe, Middle East, and Africa		Asia Pacific		Group total	
	%	SEK M	%	SEK M	%	SEK M	%	SEK M
Q4 2020/21 vs. Q4 2019/20								
Change based on constant currency	13	251	7	143	46	536	18	930
Currency effects	-14	-267	-7	-140	-15	-176	-12	-583
Reported change	-1	-16	0	3	31	360	7	347
Q4 2019/20 vs. Q4 2018/19								
Change based on constant currency	0	-5	-17	-394	-13	-160	-10	-559
Currency effects	5	100	2	40	4	50	4	190
Reported change	5	95	-16	-353	-9	-110	-7	-369
May - Apr 2020/21 vs. May - Apr 2019/20								
Change based on constant currency	23	1,136	-4	-316	5	259	6	1,079
Currency effects	-12	-581	-5	-360	-8	-462	-8	-1,403
Reported change	11	555	-10	-676	-4	-203	-2	-324
May - Apr 2019/20 vs. May - Apr 2018/19								
Change based on constant currency	-6	-321	1	81	8	385	1	146
Currency effects	6	295	3	209	6	289	5	793
Reported change	-1	-26	4	290	13	674	6	938

Fourth quarter and full year

Change net sales

	North and South America		Europe, Middle East, and Africa		Asia Pacific		Group total	
	%	SEK M	%	SEK M	%	SEK M	%	SEK M
Q4 2020/21 vs. Q4 2019/20								
Change based on constant currency	-2	-22	3	55	0	-3	1	29
Currency effects	-12	-154	-7	-103	-10	-113	-9	-371
Reported change	-14	-177	-3	-49	-10	-116	-9	-342
Q4 2019/20 vs. Q4 2018/19								
Change based on constant currency	-1	-8	-2	-39	-14	-183	-6	-230
Currency effects	5	59	3	49	3	43	4	152
Reported change	4	51	1	11	-11	-140	-2	-78
May - Apr 2020/21 vs. May - Apr 2019/20								
Change based on constant currency	-4	-187	-2	-118	11	516	1	211
Currency effects	-9	-407	-5	-289	-8	-354	-7	-1,049
Reported change	-13	-594	-7	-406	4	162	-6	-838
May - Apr 2019/20 vs. May - Apr 2018/19								
Change based on constant currency	-6	-285	9	468	6	248	3	431
Currency effects	6	267	2	123	6	226	5	616
Reported change	0	18	12	591	12	474	8	1,047

EBITDA

EBITDA is used for the calculation of operational cash conversion and the net debt/EBITDA ratio.

SEK M	Q4 2019/20	Q1 2020/21	Q2 2020/21	Q3 2020/21	Q4 2020/21
Operating result/EBIT	658	335	559	468	545
<i>Amortization intangible assets:</i>					
Capitalized development costs	199	186	163	167	169
Assets relating business combinations	29	30	30	29	28
Depreciation fixed assets	121	100	95	96	111
EBITDA	1,008	651	846	759	853

Fourth quarter and full year

Return on capital employed

Return on capital employed is a measure of the profitability after taking into account the amount of total capital used unrelated to type of financing. A higher return on capital employed indicates a more efficient use of capital. Capital employed represents the value of the balance sheet net assets that is the key driver of cash flow and capital required to run the business. It is also used in the calculation of return on capital employed.

SEK M	Apr 30, 2020	Jul 31, 2020	Oct 31, 2020	Jan 31, 2021	Apr 30, 2021
Profit before tax (12 months rolling)	1,454	1,546	1,751	1,773	1,630
Financial expenses (12 months rolling)	266	256	268	270	295
Profit before tax plus financial expenses	1,720	1,802	2,019	2,043	1,924
Total assets	28,411	26,798	25,497	25,464	24,844
Deferred tax liabilities	-545	-559	-560	-566	-515
Long-term provisions	-235	-222	-255	-264	-224
Other long-term liabilities	-73	-83	-92	-81	-71
Accounts payable	-1,025	-784	-987	-947	-1,016
Advances from customers	-4,103	-3,875	-3,881	-3,753	-3,759
Prepaid income	-2,226	-2,020	-1,985	-2,052	-2,082
Accrued expenses	-1,703	-1,432	-1,668	-1,723	-1,837
Current tax liabilities	-246	-191	-188	-210	-137
Short-term provisions	-179	-182	-182	-169	-174
Derivative financial instruments	-105	-125	-67	-41	-35
Other current liabilities	-501	-555	-665	-628	-559
Capital employed	17,472	16,769	14,968	15,030	14,435
Average capital employed (last five quarters)	14,247	15,133	15,401	15,656	15,735
Return on capital employed	12%	12%	13%	13%	12%

Return on shareholders' equity

Return on shareholders' equity measures the return generated on shareholders' capital invested in the company.

SEK M	Q4 2019/20	Q1 2020/21	Q2 2020/21	Q3 2020/21	Q4 2020/21
Net income (12 months rolling)	1,084	1,153	1,307	1,320	1,253
Average shareholders' equity excluding non-controlling interests (last five quarters)	7,967	7,977	8,007	8,070	8,069
Return on shareholders' equity	14%	14%	16%	16%	16%

Operational cash conversion

Cash flow is a focus area for management. The operational cash conversion shows the relation between cash flow from operating activities and EBITDA.

SEK M	Q4 2019/20	Q1 2020/21	Q2 2020/21	Q3 2020/21	Q4 2020/21
Cash flow from operating activities	1,244	211	535	690	1,114
EBITDA	1,008	651	846	759	853
Operational cash conversion	123%	32%	63%	91%	130%

Fourth quarter and full year

Working capital

In order to optimize cash generation, management focuses on working capital and reducing lead times between orders booked and cash received.

SEK M	Apr 30 2021	Apr 30 2020	Jan 31 2021
Working capital assets			
Inventories	2,283	2,748	2,416
Accounts receivable	3,281	3,379	3,287
Accrued income	1,772	1,526	1,831
Other operating receivables	1,116	1,202	1,261
Sum working capital assets	8,451	8,856	8,795
Working capital liabilities			
Accounts payable	1,016	1,025	947
Advances from customers	3,759	4,103	3,753
Prepaid income	2,082	2,226	2,052
Accrued expenses	1,837	1,703	1,723
Short-term provisions	174	179	169
Other current liabilities	559	501	628
Sum working capital liabilities	9,428	9,735	9,273
Net working capital	-977	-879	-478
% of 12 months net sales	-7%	-6%	-3%

Days Sales Outstanding

Days Sales Outstanding was negative 21 days at the end of April 30, 2021 (negative 36 days per April 30).

SEK M	Apr 30 2021	Apr 30 2020	Jan 31 2021
North and South America	-72	-75	-72
Europe, Middle East and Africa	57	37	46
Asia Pacific	-64	-82	-38
Group	-21	-36	-18

Net debt and net debt/EBITDA ratio

Net debt is important for understanding the financial stability of the company. Net debt and net debt/EBITDA ratio are used by management to track the debt evolution, the refinancing need and the leverage for the Group.

SEK M	Apr 30, 2020	Jul 31, 2020	Oct 31, 2020	Jan 31, 2021	Apr 30, 2021
Long-term interest-bearing liabilities	7,101	6,953	4,983	4,950	3,043
Short-term interest-bearing liabilities	1,001	895	879	831	2,141
Cash and cash equivalents and short-term investments	-6,470	-5,846	-3,913	-4,640	-4,411
Net debt	1,632	2,002	1,949	1,140	774
EBITDA (12 months rolling)	2,931	3,040	3,252	3,265	3,110
Net debt/EBITDA ratio	0.56	0.66	0.60	0.35	0.25

Fourth quarter and full year

Shareholder information

Conference call

Elekta will host a web conference at 10:00-11:00 CET on May 28 with President and CEO Gustaf Salford, and CFO Johan Adebäck. To take part of the presentation please dial the numbers or watch via the web link below.

Sweden: +46 8 505 583 73

United Kingdom: +44 333 300 9273

United States: +1 833 526 8383

<https://elekta-qreports.creo.se/210528>

Capital Markets Day	Jun 7, 2021
Annual report 2020/21	Jul 9, 2021
Annual General Meeting	Aug 25, 2021
Interim report, Q1, May-July 2021/22	Aug 25, 2021
Interim report, Q2, May-Oct 2021/22	Nov 25, 2021
Interim report, Q3, May-Jan 2021/22	Feb 24, 2022

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

For further information, please contact:

Johan Adebäck
CFO
Elekta AB (publ)
+46 70 873 33 21
johan.adeback@elekta.com

Cecilia Ketels
Head of Investor Relations
Elekta AB (publ)
+46 76 611 76 25
cecilia.ketels@elekta.com

MOSAIQ[®] Plaza

Connecting you
to every moment
of a patient's journey

MOSAIQ[®] Plaza transforms cancer care by personalizing every patient's treatment pathway. This integrated suite of digital tools ensures you achieve the highest quality decision-making while delivering value-based care—continuously adapting and optimizing based upon each unique individual patient journey.



Focus where
it matters.

elekta.com/mosaiqplaza

